Biohaven Lands Strategic $600M Deal with Oberland Capital to Fuel Troriluzole Launch and Pipeline Growth

New Haven, CT, April 28, 2025 (PRNewswire) -- Biohaven Ltd. has secured up to $600 million in non-dilutive financing from Oberland Capital to advance its pipeline, particularly troriluzole for spinocerebellar ataxia. The deal includes $250 million upfront, with further funds tied to regulatory milestones and strategic opportunities. This agreement bolsters Biohaven's financial flexibility ahead of potential FDA approval and underscores investor confidence in its innovative therapies.

Read full article here.